Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Shimizu, Masanori; Suzuki, Kunihiro; Kato, Kanako; Jojima, Teruo; Iijima, Toshie; Murohisa, Toshimitsu; Iijima, Makoto; Takekawa, Hidehiro; Usui, Isao; Hiraishi, Hideyuki; Aso, Yoshimasa

doi:10.1111/dom.13520

Public

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Shared by NobleBlocks on Oct 2, 2018 • 12:00 AM UTC

Authors:

Masanori Shimizu

Kunihiro Suzuki

Kanako Kato

Abstract

Aims To investigate the effects of dapagliflozin on liver steatosis and fibrosis evaluated in patients with type 2 diabetes and non‐alcoholic fatty liver disease (NAFLD). Materials and methods In a randomized, active‐controlled, open‐label trial, 57 patients with type 2 diabetes and NAFLD were rando...

Discussions